𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis

✍ Scribed by Toshihiko Hidaka; Kimihiro Suzuki; Makoto Kawakami; Makoto Okada; Kouji Kataharada; Tadashi Shinohara; Mitsuyo Takamizawa-Matsumoto; Fumitaka Ohsuzu


Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
84 KB
Volume
16
Category
Article
ISSN
0733-2459

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

We attempted to determine whether various cytokine levels in the serum and synovial fluid (SF) of rheumatoid arthritis (RA) patients are influenced by the performance of filtration leukocytapheresis (LCP). The filtration LCP procedure that used a Cellsorba® column (LCP group: n=22; responder subgroup: n=17, non‐responder subgroup: n=5) or sham apheresis (control group; n=7) was repeated three times at 1‐week intervals. Serum (LCP group, n=22; control group, n=7) and SF (LCP group, n=6; control group, n=3) samples were collected before and after LCP. Levels of tumor necrosis factor α (TNFα), interleukins (IL‐1β, IL–2, IL‐6, IL‐8, IL‐10, and IL‐15), granulocyte–macrophage colony–stimulating factor (GM‐CSF), monocyte chemoattractant protein–1 (MCP‐1), RANTES were measured by an enzyme‐linked immunosorbent assay. Serum TNFα, IL‐15, and RANTES were significantly reduced only in the LCP group. Serum IL‐10 significantly increased only in the LCP group. In the LCP subgroup, serum IL‐15, GM‐CSF, and RANTES levels were reduced significantly, while serum IL‐10 levels increased significantly only in the responder group after treatment. Serum TNFα levels were reduced significantly in both subgroups. Changes in serum IL‐10 correlated positively with the improvement of patient's assessment of pain and global severity, and physician's assessment of global severity. These results indicate that the removal of leukocytes from the peripheral blood of RA patients provokes dynamic changes in some cytokine levels in the serum and/or synovial fluid. These changes may explain some of the mechanisms by which the articular symptoms are improved by filtration LCP. J. Clin. Apheresis. 16:74–81, 2001. © 2001 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Soluble interleukin-2 receptor: Elevated
✍ A. B. Carpenter; C. H. Eisenbeis; Jr.; S. Carrabis; M. C. Brown; S. H. Ip 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 452 KB

Soluble interleukin-2 receptor (sll-2R) levels were quantitated in the seum and synovial fluid (SF) of patients with rheumatoid arthritis (RA) and degenerative joint disease (DJD). A sandwich immunoassay, employing two monoclonal antiodies against distinct epitopes on the lL-2R, was utilized for mea

Elevated soluble interleukin-2 receptor
✍ E. C. Keystone; K. M. Snow; C. Bombardier; Chi-Hsing Chang; D. L. Nelson; L. A. 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 611 KB

In a previous study, we used an enzyme-linked immunosorbent assay to measure soluble human interleukin-2 receptors (IL3R), and found that when activated lymphocytes produce cell-associated IL-2R, they also release a soluble form of IL3R into culture supernatants in vitro. Soluble IL-2R have also bee